386 related articles for article (PubMed ID: 33191774)
1. Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis.
Ibrahim ME; Castillo-Mancilla JR; Yager J; Brooks KM; Bushman L; Saba L; Kiser JJ; MaWhinney S; Anderson PL
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):421-428. PubMed ID: 33191774
[TBL] [Abstract][Full Text] [Related]
2. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
[TBL] [Abstract][Full Text] [Related]
3. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288
[TBL] [Abstract][Full Text] [Related]
4. Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.
van den Elshout MA; Hoornenborg E; Coyer L; Anderson PL; Davidovich U; de Vries HJ; Prins M; Schim van der Loeff MF;
Sex Transm Infect; 2023 Aug; 99(5):303-310. PubMed ID: 37258273
[TBL] [Abstract][Full Text] [Related]
5. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
Hendrix CW; Andrade A; Bumpus NN; Kashuba AD; Marzinke MA; Moore A; Anderson PL; Bushman LR; Fuchs EJ; Wiggins I; Radebaugh C; Prince HA; Bakshi RP; Wang R; Richardson P; Shieh E; McKinstry L; Li X; Donnell D; Elharrar V; Mayer KH; Patterson KB
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):32-43. PubMed ID: 26414912
[TBL] [Abstract][Full Text] [Related]
6. Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.
Goldwirt L; Bauer R; Liegeon G; Charreau I; Delaugerre C; Cotte L; Pialou G; Cua E; Laghzal A; Buschman L; Anderson PL; Mourah S; Meyer L; Molina JM;
J Antimicrob Chemother; 2021 Sep; 76(10):2675-2680. PubMed ID: 34278433
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.
Stranix-Chibanda L; Anderson PL; Kacanek D; Hosek S; Huang S; Nematadzira TG; Taulo F; Korutaro V; Nakabiito C; Masenya M; Lypen K; Brown E; Ibrahim ME; Yager J; Wiesner L; Johnston B; Amico KR; Rooney JF; Chakhtoura N; Spiegel HML; Chi BH;
Clin Infect Dis; 2021 Oct; 73(7):e1893-e1900. PubMed ID: 33341883
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
Yager JL; Brooks KM; Castillo-Mancilla JR; Nemkov C; Morrow M; Peterson S; Ibrahim M; Bushman L; Kiser JJ; MaWhinney S; Anderson PL
AIDS; 2021 Dec; 35(15):2481-2487. PubMed ID: 34482350
[TBL] [Abstract][Full Text] [Related]
9. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
[TBL] [Abstract][Full Text] [Related]
10. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
Havens PL; Tamhane A; Stephensen CB; Schuster GU; Gordon CM; Liu N; Wilson CM; Hosek SG; Anderson PL; Kapogiannis BG; Mulligan K
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):123-128. PubMed ID: 30280906
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Castillo-Mancilla JR; Zheng JH; Rower JE; Meditz A; Gardner EM; Predhomme J; Fernandez C; Langness J; Kiser JJ; Bushman LR; Anderson PL
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):384-90. PubMed ID: 22935078
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring.
Niu X; Kubiak RW; Siriprakaisil O; Klinbuyaem V; Sukrakanchana PO; Cressey R; Okochi H; Gandhi M; Cressey TR; Drain PK
Open Forum Infect Dis; 2022 Aug; 9(8):ofac405. PubMed ID: 36004315
[TBL] [Abstract][Full Text] [Related]
13. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
[TBL] [Abstract][Full Text] [Related]
14. Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP.
Jongen VW; Hoornenborg E; van den Elshout MA; Boyd A; Zimmermann HM; Coyer L; Davidovich U; Anderson PL; de Vries HJ; Prins M; Schim van der Loeff MF;
J Int AIDS Soc; 2021 May; 24(5):e25708. PubMed ID: 33973373
[TBL] [Abstract][Full Text] [Related]
15. Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.
Moore M; Stansfield S; Donnell DJ; Boily MC; Mitchell KM; Anderson PL; Delany-Moretlwe S; Bekker LG; Mgodi NM; Celum CL; Dimitrov D
Nat Med; 2023 Nov; 29(11):2748-2752. PubMed ID: 37798438
[TBL] [Abstract][Full Text] [Related]
16. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
Grant RM; Pellegrini M; Defechereux PA; Anderson PL; Yu M; Glidden DV; O'Neal J; Yager J; Bhasin S; Sevelius J; Deutsch MB
Clin Infect Dis; 2021 Oct; 73(7):e2117-e2123. PubMed ID: 32766890
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
Pyra M; Anderson PL; Hendrix CW; Heffron R; Mugwanya K; Haberer JE; Thomas KK; Celum C; Donnell D; Marzinke MA; Bukusi EA; Mugo NR; Asiimwe S; Katabira E; Baeten JM;
AIDS; 2018 Aug; 32(13):1891-1898. PubMed ID: 29894385
[TBL] [Abstract][Full Text] [Related]
18. Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
Tapsoba JD; Cover J; Obong'o C; Brady M; Cressey TR; Mori K; Okomo G; Kariithi E; Obanda R; Oluoch-Madiang D; Chen YQ; Drain P; Duerr A
PLoS Med; 2022 Sep; 19(9):e1004097. PubMed ID: 36095005
[TBL] [Abstract][Full Text] [Related]
19. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.
Spinelli MA; Glidden DV; Anderson PL; Gandhi M; Cohen S; Vittinghoff E; Coleman ME; Scott H; Bacon O; Elion R; Kolber MA; Buchbinder SP; Liu AY
J Acquir Immune Defic Syndr; 2019 Jun; 81(2):158-162. PubMed ID: 31095005
[TBL] [Abstract][Full Text] [Related]
20. Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.
Castillo-Mancilla JR; Searls K; Caraway P; Zheng JH; Gardner EM; Predhomme J; Bushman LR; Anderson PL; Meditz AL
AIDS Res Hum Retroviruses; 2015 Apr; 31(4):428-32. PubMed ID: 25328112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
